PRESS RELEASE BY THE OFFICE OF THE DEPUTY PRIME MINISTER AND THE MINISTRY FOR HEALTH: Malta insists on medicine price transparency during negotiations with the Pharma industry

​Open dialogue and transparency in medicines pricing are imperative to ensure fair pricing for consumers, continued access to new medicines and the sustainability of the European healthcare systems. This was the message conveyed by the Deputy Prime Minister and Minister for Health Chris Fearne during meetings held in Brussels with representatives of the pharmaceutical industries and European Consumer Organisations.

It was during the Maltese Presidency of the Council of the EU in 2017 that a new impetus was given to the discussions with the pharmaceutical industry. On Malta’s initiative, the Valletta Declaration Group was established, which now includes ten EU member states, together accounting for approximately 30% of the EU population. 
Malta’s initiative is aimed at securing cheaper prices for new medicines through greater transparency in pricing negotiations. 
The Deputy Prime Minister is insisting on countries being at liberty to disclose the final prices they negotiate with the pharmaceutical companies. Currently, pharmaceutical companies prohibit the publication of these prices for commercial reasons. However, this is leading to pricing discrepancies with countries being charged different prices for the same medicine procured. 
The Maltese Government is steadfast in its determination to continue leading this initiative forward in the interest of all European patients, and will be working in the near future, to put this matter on the Council of the EU’s agenda. The final objective is to have a legal framework for transparency in negotiations between governments and the industry.